No aHUS recurrence, graft rejection or severe infection ... new mechanism-based recommendations that address the underlying pathophysiology of the disease (uncontrolled complement activation ...

NHS patients in Scotland with the rare disease atypical haemolytic uremic syndrome (aHUS) will now be able to access treatment with Alexion's Ultomiris, ahead of their counterparts in England and ...

While PNH and aHUS are rare diseases, that has not stopped Soliris and Ultomiris making blockbuster sales, with AZ reporting sales of $2 billion and $853 million respectively for the two drugs in ...